/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)
DexCom Earnings: Another Solid Quarter Highlights Operational Improvements in 2026
DexCom's second-quarter results included solid 11% year-over-year growth in US revenue, while international sales rose more strongly at 16% in constant currency.
DexCom Inc DXCM
Bulls Say, Bears Say
Bulls
DexCom's G7 product is significantly less expensive and offers a thinner profile and faster warm-up time than the G6.
Bears
Considering DexCom's sensors are already the most accurate, there's less opportunity for significant improvements on that dimension, compared with key competitors.
News
-
Dexcom Reports Second Quarter 2026 Financial Results
-
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm
-
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
-
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
-
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
-
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Dexcom Further Advances Vision of Glucose Biosensing for All
Trading Information
- Previous Close Price
- $84.75
- Day Range
- $84.62–88.15
- 52-Week Range
- $54.12–88.15
- Bid/Ask
- $87.84 / $87.86
- Shares Outstanding
- 377.36M
- Market Cap
- $33.03B
- Volume/Avg
- 5M / 6M
Key Statistics
- Price/Earnings (Normalized)
- 33.22
- Price/Sales
- 6.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 3.37%
Company Profile
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 11,100
- Website
- https://www.dexcom.com
Competitors
Valuation
|
Metric
|
DXCM
|
PODD
|
ABT
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.22 | 26.24 | 20.49 |
Price/Book Value | 12.20 | 6.89 | 3.65 |
Price/Sales | 6.78 | 3.30 | 4.04 |
Price/Cash Flow | 21.72 | 16.35 | 17.22 |
Price/Earnings
DXCM
PODD
ABT
Financial Strength
|
Metric
|
DXCM
|
PODD
|
ABT
|
|---|---|---|---|
Quick Ratio | 1.37 | 1.51 | 0.97 |
Current Ratio | 1.73 | 2.48 | 1.38 |
Interest Coverage | 80.16 | 9.04 | 10.40 |
Quick Ratio
DXCM
PODD
ABT
Profitability
|
Metric
|
DXCM
|
PODD
|
ABT
|
|---|---|---|---|
Return on Assets (Normalized) | 14.49% | 13.71% | 9.71% |
Return on Equity (Normalized) | 36.44% | 30.67% | 17.95% |
Return on Invested Capital (Normalized) | 20.31% | 18.70% | 13.03% |
Return on Assets
DXCM
PODD
ABT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|H$Qq^l | LOCK|Z!$Y | $187B | |||
| Stryker Corp
SYK
| LOCK|TtQx^V^ | LOCK|W#T | $130B | |||
| Medtronic PLC
MDT
| LOCK|wZJ#$Ds | LOCK|vW>GK | $112B | |||
| Boston Scientific Corp
BSX
| LOCK|J$J#%& | LOCK|Xq#% | $71B | |||
| Edwards Lifesciences Corp
EW
| LOCK|hp<pPQn | LOCK|>V^h | $52B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|w?rNrG | LOCK|@Bd | $32B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|&v | LOCK|!%& | $26B | |||
| Steris PLC
STE
| LOCK|#xcT>z | LOCK|g>Bp# | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|r@&t$j&R | LOCK|#k | $18B |
United States